Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2014
09/25/2014WO2014152536A2 Inhibitors of leukotriene a4 hydrolase
09/25/2014WO2014152518A2 Inhibitors of leukotriene a4 hydrolase
09/25/2014WO2014152514A1 Combination of two antivirals for treating hepatitis c
09/25/2014WO2014152504A1 Method of treating vitamin b12 deficiency
09/25/2014WO2014152494A1 Prodrugs of fumarates and their use in treating various deseases
09/25/2014WO2014152466A1 Taste masking of anesthetics and analgesics
09/25/2014WO2014152454A1 Transdermal drug delivery system containing rivastigmine
09/25/2014WO2014152450A1 Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
09/25/2014WO2014152444A1 Histone deacetylase inhibitors
09/25/2014WO2014152420A2 Product and method for treating diarrhea
09/25/2014WO2014152389A1 Imaging agent for detection of diseased cells
09/25/2014WO2014152382A1 Transdermal delivery of sildenafil and other phosphodiesterase type 5 inhibitors
09/25/2014WO2014152360A1 Porous composites with paclitaxel crystals
09/25/2014WO2014152317A2 Methods of treating gonorrhea infections using quinolone antibiotics
09/25/2014WO2014152280A1 Transdermal formulations of fluticasone
09/25/2014WO2014152275A1 Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
09/25/2014WO2014152270A1 Salt of omecamtiv mecarbil and process for preparing salt
09/25/2014WO2014152269A1 Pharmaceutical soft gelatin capsule dosage form with modified guar gum
09/25/2014WO2014152263A1 Exo olefin-containing nuclear transport modulators and uses thereof
09/25/2014WO2014152261A1 Substituted 7-deazapurine compounds
09/25/2014WO2014152236A1 Heterocyclic compounds and their uses
09/25/2014WO2014152229A2 Inhibitors of leukotriene a4 hydrolase
09/25/2014WO2014152226A1 Pharmaceutical soft gelatin capsule dosage form
09/25/2014WO2014152215A1 SALT FORMS OF (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
09/25/2014WO2014152198A1 Heterocyclic compounds and their uses
09/25/2014WO2014152196A1 Pharmaceutical composition of s-ketamine hydrochloride
09/25/2014WO2014152182A1 Deuterated heterocyclic inhibitors of necroptosis
09/25/2014WO2014152144A1 Muscarinic agonists
09/25/2014WO2014152134A1 Tripeptide epoxy ketone protease inhibitors
09/25/2014WO2014152127A1 Dipeptide and tripeptide epoxy ketone protease inhibitors
09/25/2014WO2014152122A2 Methods of altering vascular permeability and uses thereof
09/25/2014WO2014152114A1 Heteroaromatic compounds as btk inhibitors
09/25/2014WO2014152029A2 Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
09/25/2014WO2014152018A1 Octahydrocyclopentapyrroles, their preparation and use
09/25/2014WO2014152016A1 Leucine and nicotinic acid reduces lipid levels
09/25/2014WO2014152013A1 4-phenylpiperidines, their preparation and use
09/25/2014WO2014152009A1 Transdermal formulations of laquinimod
09/25/2014WO2014152007A1 Films and drug delivery systems for rizatriptan
09/25/2014WO2014151975A1 Film delivery system for active ingredients
09/25/2014WO2014151959A1 N-alkyl-2-phenoxyethanamines, their preparation and use
09/25/2014WO2014151958A1 Beta-lactamase inhibitors
09/25/2014WO2014151953A1 Compounds and methods for inducing chondrogenesis
09/25/2014WO2014151919A1 Factor h for transplantation
09/25/2014WO2014151900A1 Protein kinase c inhibitors and uses thereof
09/25/2014WO2014151899A1 Polycyclic estrogen receptor modulators and uses thereof
09/25/2014WO2014151863A1 Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
09/25/2014WO2014151853A1 Methods of treating bladder cancer
09/25/2014WO2014151835A1 Locked nucleic acid inhibitor of mir-145 and uses thereof
09/25/2014WO2014151797A1 Extended release formulations resistant to alcohol dose dumping
09/25/2014WO2014151784A1 Compounds and compositions for the treatment of parasitic diseases
09/25/2014WO2014151761A1 Novel choline kinase inhibitors
09/25/2014WO2014151752A1 Composition and methods for the treatment of peripheral nerve injury
09/25/2014WO2014151742A1 Formulation containing carbidopa, levodopa, and entacapone
09/25/2014WO2014151729A1 Compounds and compositions for the treatment of parasitic diseases
09/25/2014WO2014151719A1 Sublingual formulations including geranylgeranylacetone and geranylgeranylacetone derivatives
09/25/2014WO2014151703A1 Ocular formulations
09/25/2014WO2014151697A1 Therapeutic uses for geranylgeranyl acetone and derivatives thereof
09/25/2014WO2014151682A1 Pyrimidine compounds as kinase inhibitors
09/25/2014WO2014151620A1 5-thiazolecarboxamide dervatives and their use as btk inhibitors
09/25/2014WO2014151575A1 Solid oral dosage formulation of hcv inhibitor in the amorphous state
09/25/2014WO2014151567A1 Oral care compositions containing deoxy sugar antimetabolites
09/25/2014WO2014151547A1 Sovaprevir tablets
09/25/2014WO2014151530A1 Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products
09/25/2014WO2014151529A1 Therapeutic agents and methods for the treatment of dna repair deficiency disorders
09/25/2014WO2014151523A1 Compositions and products for infectious or inflammatory diseases or conditions
09/25/2014WO2014151517A1 Methods of improving microvascular integrity
09/25/2014WO2014151492A1 Compositions and methods for transdermal delivery of tertiary amine drugs
09/25/2014WO2014151472A1 Sodium channel modulators for the treatment of pain
09/25/2014WO2014151462A1 Novel breathing control modulating compounds, and methods of using same
09/25/2014WO2014151451A1 Inhibition of leukotriene synthesis and activity in the treatment of sonic hedgehog-associated medulloblastoma
09/25/2014WO2014151444A1 Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
09/25/2014WO2014151387A1 Stable transdermal amphetamine compositions and methods of manufacture
09/25/2014WO2014151386A1 Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
09/25/2014WO2014151380A1 1,2,6-substituted benzimidazoles as flap modulators
09/25/2014WO2014151367A1 1,2,5-substituted benzimidazoles as flap modulators
09/25/2014WO2014151350A1 Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body
09/25/2014WO2014151347A1 Minocycline derivatives
09/25/2014WO2014151331A1 Tinted antiseptic solutions having improved stability
09/25/2014WO2014151329A1 Particles for aerosolizing apparatus
09/25/2014WO2014151304A1 Therapeutic methods and compositions utilizing cyclohexenone compounds
09/25/2014WO2014151258A1 Substituted pyridine derivatives useful as c-fms kinase inhibitors
09/25/2014WO2014151253A1 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide for the treatment of hodgkin's lymphoma
09/25/2014WO2014151247A1 Oxabicyclo [2.2.2] acid gpr120 modulators
09/25/2014WO2014151180A1 Treatment of psoriatic arthritis using apremilast
09/25/2014WO2014151147A1 Combination of kinase inhibitors and uses thereof
09/25/2014WO2014151142A1 Modulators of methyl modifying enzymes, compositions and uses thereof
09/25/2014WO2014151113A1 Compositions and methods for utilization of algal compounds
09/25/2014WO2014151109A1 Formulations of water-soluble derivatives of vitamin e and compositions containing same
09/25/2014WO2014151107A1 Wound healing compositions
09/25/2014WO2014151085A1 Beraprost isomer as agent for the treatment of viral infection
09/25/2014WO2014150996A1 Cancer treatment
09/25/2014WO2014150959A2 Method and products for enhancing cellular uptake of drug and dietary supplements
09/25/2014WO2014150935A1 Method and products for enhancing drug and dietary supplement bioavailability
09/25/2014WO2014150899A1 Topical ophthalmic formulations for treating migraine
09/25/2014WO2014150873A1 Sequestrants of advanced glycation end product (age) precursors
09/25/2014WO2014150829A1 Medicament for treatment of cancer, cardiovascular diseases and inflammation
09/25/2014WO2014150790A1 Pak1 inhibition for treatment of acute myeloid leukemia and myelodysplastic syndromes
09/25/2014WO2014150718A1 Intra-testicular injection of immunogens
09/25/2014WO2014150687A1 Use of specific carbohydrate systems during pregnancy for improving bone development and formation and/or for improving cognitive and cns development in offspring
09/25/2014WO2014150660A1 Racecadotril lipid compositions
1 ... 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 ... 7860